Novartis India Moves On From Glivec Patent Loss To Launch More Drugs
This article was originally published in PharmAsia News
Novartis India, which lost a patent battle for its cancer drug Glivec (imatinib) a year ago, has shaken off the loss and launched drugs in India along with more than a dozen generics in the interim.
You may also be interested in...
Generic OTC paracetamol and ibuprofen pack prices are gradually returning to pre-COVID levels, according to market analysts Wavedata. But a second wave could drive prices back up again.
As one of the leading players in the US, albeit with a declining core business, Sandoz is naturally watching developments from the Federal Circuit’s precedential ruling on induced infringement for carved out indications. Management discussed the topic as Sandoz reported third-quarter financials.
With the India business on the road to recovery and the US growth outlook muted, Torrent hopes to keep the boat steady in fiscal 2021. It also expects an order in Q3 in a patent infringement case pertaining to AstraZeneca’s Farxiga, where it and multiple Indian firms are seeking to launch generic versions.